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Abstract
Angiosarcoma (ASA) in humans and hemangiosarcoma
(HSA) in dogs are deadly neoplastic diseases charac-
terized by an aggressive growth of malignant cells with
endothelial phenotype, widespread metastasis, and
poor response to chemotherapy. Galectin-3 (Gal-3), a
B-galactoside–binding lectin implicated in tumor pro-
gression and metastasis, endothelial cell biology and
angiogenesis, and regulation of apoptosis and neo-
plastic cell response to cytotoxic drugs, has not been
studied before in tumors arising from malignant endo-
thelia. Here, we tested the hypothesis that Gal-3 could be
widely expressed in human ASA and canine HSA and
could play an important role in malignant endothelial cell
biology. Immunohistochemical analysis demonstrated
that 100% of the human ASA (10 of 10) and canine
HSA (17 of 17) samples analyzed expressed Gal-3.
Two carbohydrate-based Gal-3 inhibitors, modified cit-
rus pectin (MCP) and lactulosyl-L-leucine (LL), caused
a dose-dependent reduction of SVR murine ASA cell
clonogenic survival through the inhibition of Gal-3 anti-
apoptotic function. Furthermore, both MCP and LL sen-
sitized SVR cells to the cytotoxic drug doxorubicin to a
degree sufficient to reduce the in vitro IC50 of doxo-
rubicin by 10.7-fold and 3.6-fold, respectively. These re-
sults highlight the important role of Gal-3 in the biology
of ASA and identify Gal-3 as a potential therapeutic tar-
get in tumors arising from malignant endothelial cells.
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Introduction
Human angiosarcoma (ASA) is a rare but deadly malignant
vascular tumor that accounts for 1% to 2% of all sarcomas.
ASA is aggressive and tends to recur locally, to spread widely,
and to possess a high rate of lymph node and systemic metas-
tases [1]. It is characterized by early local and systemic dis-
semination, restricting indications for surgical resection to a
small number of patients. The treatment of human ASA can be
challenging and futile [1]. Chemotherapy and radiation therapy
may be indicated as either adjuvant or primary treatment, but
their use is often limited by the poor physical condition of pa-
tients. The rate of tumor-related death in patients with ASA is
high, with survival ranging from 6 to 9 months, regardless of
the treatment chosen, and with the reported 5-year survival rate
being < 20% [2–5].
Canine hemangiosarcoma (HSA) is a common fatal cancer
of dogs arising from transformed vascular endothelial cells
that resembles human ASA [6,7] and can serve as a model
of metastatic ASA in humans [7]. HSA, which also has an
endothelial phenotype, occurs more frequently in dogs than
in any other species, comprising up to 5% to 7% of primary
noncutaneous malignant neoplasms. This tumor affects almost
every dog breed, but large-breed dogs and those that are lightly
pigmented or sparsely haired appear to be at a higher risk. HSA
can arise in any tissue with blood vessels, but the most
common sites in dogs are the spleen (50–65%), right atrium/
auricle (3–25%), subcutaneous tissues (13–17%), and the
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liver (5–6%) [8]. Similar to human ASA, canine HSA is
characterized by early and aggressive metastasis. Local
infiltration and systemic metastasis are common growth
patterns, and metastatic sites are widespread. Morbidity
and mortality in dogs with HSA are often due to acute internal
hemorrhage secondary to tumor rupture. Despite surgery
and intensive chemotherapy, the median survival time for
dogs is a little more than 6 months [8,9].
Based on poor response to available therapies, there is a
need to identify molecular targets in ASA that would facilitate
the development of novel mechanism-based therapeutic ap-
proaches. Spontaneously developing canine HSA could serve
as a model system for validating these targets and for testing
new therapeutic modalities. Here, we suggest that one such
potential target could be galectin-3 (Gal-3; Mr f 31 kDa),
a member of the family of mammalian carbohydrate-binding
proteins with an affinity to terminal b-galactose and with highly
conserved features in the carbohydrate-binding domain [10].
Gal-3 is prominently expressed in a variety of neoplasms,
including stomach [11,12], colon [13], breast [14], bladder
[15,16], and thyroid [17] cancers. This carbohydrate-binding
protein is involved in many physiological and pathological pro-
cesses, such as cell growth and differentiation [18,19], cell–
cell and cell–extracellular matrix adhesions [20], metastasis
[21], and regulation of apoptosis [18,22–26]. Furthermore,
Gal-3 has been shown to control tumor cell sensitivity to che-
motherapy through the regulation of apoptotic responses to
cytotoxic drugs [23]. In several experimental systems, Gal-3
expression has been associated with increased malignant and
metastatic phenotype [24–28]. In addition, Gal-3 is intimately
involved in endothelial biology and angiogenesis [29], as well
as in endothelial cell morphogenesis [29]. To date, however,
Gal-3 has not been studied in tumors arising from malignant
endothelia, such as human ASA and/or canine HSA.
Given the importance of this carbohydrate-binding protein
in both malignant transformation and endothelial cell biology,
we hypothesize that Gal-3 could be prominently expressed
in tumors arising from malignant endothelia and could serve
as a potential therapeutic target in these neoplasms. Here,
we tested this hypothesis by analyzing Gal-3 expression in
archived specimens of human ASA and canine HSA, and
by investigating the consequences of inhibiting Gal-3 function
in a murine HSA cell line using two carbohydrate-based Gal-3
inhibitors, modified citrus pectin (MCP) [29–31] and lactulosyl-
L-leucine (LL) [32,33].
Materials and Methods
Chemicals and Reagents
All chemicals and reagents were of analytic grade and,
unless otherwise specified, were from Sigma Chemical
Co. (St. Louis, MO). The hybridoma cell line TIB-166, which
produces rat monoclonal anti –Gal-3 antibody, was ob-
tained from the American Type Culture Collection (ATCC;
Manassas, VA). The preparation of MCP and LL has been
described elsewhere [29–33]. The carbohydrate specificity
of LL and MCP has been investigated previously. Specifi-
cally, the carbohydrate specificity of MCP anti–Gal-3 effect
was controlled using lactose, sucrose, and unmodified citrus
pectin [31]. The carbohydrate specificity of LL anti–Gal-3
action was controlled using lactose and maltose [21]. Fur-
thermore, in one of the earlier studies [20], we specifically
synthesized as a control compound for LL the glycoamine
lactitol-L-leucine, which differs from LL only in that glucose
in lactitol is in open (alcohol) form; this modification com-
pletely abrogated the compound’s anti–Gal-3 activity.
Tissue Samples
Archived formalin-fixed paraffin-embedded (FFPE) tis-
sues from 10 surgically removed human ASA from the Uni-
versity of Missouri Healthcare System and 17 canine HSA
from the University of Missouri Veterinary Medical Diagnostic
Laboratory (VMDL) were used for Gal-3 expression and
immunohistochemical analyses. Normal canine tissues from
patients without HSA at the VMDL were also analyzed.
Cancer Cell Lines and Cultures
The murine HSA cell line SVR was obtained from the
ATCC. This cell line was developed from murine endothelial
cells isolated from pancreatic islets of C57BL/6 adult mice,
which were transduced with a retrovirus encoding H-ras and
hygromycin resistance [34]. SVR cells were grown as mono-
layers on plastic at 37jC in a 5% CO2/95% air atmosphere
using RPMI 1640 supplemented with 10% fetal bovine
serum, L-glutamine, and gentamycin, and subcultured every
2 to 3 days.
Immunohistochemistry
Gal-3 protein was localized in FFPE tissue sections of
human ASA and canine HSA by immunohistochemistry
using a 1:100 dilution of rat primary monoclonal anti–Gal-
3 antibody TIB-166. Briefly, deparaffinized and steamer-
treated sections were treated with 3% hydrogen peroxide
for 10 minutes to block endogenous peroxidase. Following
an avidin–biotin block (SP2001; Vector, Burlingame, CA),
a rinse with Tris buffer (TB), and a 10-minute protein block
(XO 909; Dako, Carpinteria, CA), the sections were incu-
bated with primary anti–Gal-3 antibody overnight at 4jC
(1:100 dilution). On the following morning, slides were rinsed
in TB and incubated with rabbit anti-rat IgG (1:1500 dilution,
A5795; Sigma) for 30 minutes at room temperature. After
an additional rinse with TB, a Link step (LSAB+; Dako) for
30 minutes at room temperature, and another TB rinse and
Label step (LSAB+; Dako) for 30 minutes, the slides were
washed thoroughly with distilled water and incubated with
3,3V-diaminobenzidine (K3466; Dako) for 5 to 10 minutes at
room temperature. Hematoxylin counterstaining was per-
formed, followed by dehydration and coverslipping. Negative
controls consisted of omission of the primary antibody.
Endothelial cell phenotype was identified by immunostaining
the sections with a 1:800 dilution of primary rabbit polyclonal
antibody and von Willebrand factor. In spleen samples,
brown granules of hemosiderin were identified with Prussian
blue stain for iron. For analyzing Gal-3 expression in the
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murine SVR HSA cell line, the cells were grown until 60% to
80% confluent directly on microscope slides using the cham-
ber slide system (NalgeNunc, Naperville, IL). After fixing and
permeabilizing cells overnight in 2% formaldehyde solution
in phosphate-buffered saline (PBS), Gal-3 immunostaining
was performed exactly as described for ASA and HSA
samples (see above), including negative control omitting
the primary antibody, counterstaining, and coverslipping.
Computer-Assisted Image Analysis
Sections were photographed with an Olympus BX60
photomicroscope (Olympus, Center Valley, PA) and Spot
Insight Color digital camera (Diagnostic Instruments, Sterling
Heights, MI). The area of positive staining for Gal-3 was
calculated as a percentage of the total section area using
ImageProPlus software (Media Cybernetics, Bethesda, MD).
Clonogenic Survival
SVR cells, grown until 50% to 60% confluent, were
harvested using a nonenzymatic cell dissociation reagent
and pipetted to produce a single-cell suspension. Next, cells
were plated at low density (200 cells/well) in quadruplicate in
24-well culture plates without (control) or with indicated
concentrations of the compounds tested. Seven days later,
the cells were fixed with 2% formaldehyde in PBS and
stained with hematoxylin, and colonies of z 15 cells were
scored. Only cells with a viability ofz 95%, as determined by
trypan blue dye exclusion, were used for these experiments.
Apoptosis Induction Experiments
Apoptosis studies were performed using the TdT-mediated
deoxyuridine triphosphate nick end labeling (TUNEL) method.
SVR cells, grown until 50% to 60% confluent, were harvested
using a nonenzymatic cell dissociation reagent and pipetted
to produce a single-cell suspension. Next, SVR cells were
plated at low density (200 cells/well) in quadruplicate using
four-well chamber slides without (control) or with Gal-3 inhibi-
tors tested (LL at 1.0 mM, or MCP at a final concentration
of 0.25%). After 24 hours, the cells were fixed in 2% formal-
dehyde in PBS. TUNEL assay was performed using the
in situ Cell Death Detection kit POD (Roche Diagnostics,
Indianapolis, IN) according to the manufacturer’s protocol,
and apoptotic and nonapoptotic cells were scored.
Western Blot Analysis
SVR cells, grown until 50% to 60% confluent, were har-
vested, washed with PBS, and resuspended with cell lysis
buffer (C3228; Sigma) supplemented with protease inhibi-
tor cocktail (P8340; Sigma) at a ratio of 1:10 (vol/vol). The
suspension was centrifuged at 10,000 rpm for 10 minutes.
Protein concentrations were determined using protein as-
say reagent (Bio-Rad, Hercules, CA). A 30-mg aliquot of
the total cellular protein was resolved on a 10% Nu Page
Bis Tris gel (Invitrogen, Carlsbad, CA). Proteins were trans-
ferred onto a nitrocellulose membrane (Invitrogen). After
blocking with 5% nonfat milk, membranes were reacted with
the anti–Gal-3 antibody at a 1:200 dilution, followed by goat
anti-rat IgG secondary antibody conjugated to horseradish
peroxidase (A5795; Sigma) at a 1:8000 dilution in 5% non-
fat milk in Tris-buffered saline Tween-20 solution. Expression
levels were detected using chemical luminescence (En-
hanced Chemical Luminescence, RPN 2132; Amersham,
Piscataway, NJ).
Statistical Analysis
Statistical analysis of data was performed using GraphPad
Prism version 4 software (GraphPad Software, Inc., San
Diego, CA). Two-tailed t-test was used to assess the statis-
tical significance of data. Bar graphs represent mean ±
standard deviation. The significance level was set at P < .05.
Results
Gal-3 Expression in Human ASA and Canine HSA
Routine immunohistochemical labeling protocols were
used to detect Gal-3 in FFPE tissue sections of human ASA
and canine HSA using TIB-166 anti–Gal-3 monoclonal anti-
body. We evaluated the expression of Gal-3 in 10 archived
human ASA and 17 canine HSA samples (Figure 1). The
intensity of Gal-3 immunolabeling was evaluated semi-
quantitatively by three independent observers (K.D.J.,
J.R.T., and V.V.G.) as follows: (0) negative; (1+) 1% to 10%
positive cells; (2+) 10% to 50% positive cells; and (3+) 50%
to 100% positive cells. One hundred percent (10 of 10 human
cases and 17 of 17 canine cases) of the specimens tested
were positive for Gal-3. These results are summarized in
Tables 1 and 2.
In addition, we performed computer-assisted image analy-
ses (Figure 1, E–H ) using ImageProPlus software for quan-
tification of Gal-3 expression in tumor tissues versus negative
controls. The results of computer-assisted analyses corre-
lated well with the scores made by the observers in samples
with high (3+) and moderate (2+) Gal-3 expressions. In sam-
ples with negative (0) or weak (1+) Gal-3 expression, however,
computer-assisted analyses often yielded elevated (false posi-
tive) scores.
In the majority of cases, hematoxylin and eosin (H&E)
staining (Figure 2A), Gal-3 staining (Figure 2B), nonimmune
control (Figure 2C), and factor VIII–related antigen (von
Willebrand factor) staining (Figure 2D) were sufficient for
characterizing samples and for analyzing the level of Gal-3
expression. However, in canine cases associated with HSA
localization in the spleen, brown staining was also observed
in normal spleen tissue even on H&E slides (Figure 2E, black
arrows) and in nonimmune controls (Figure 2G, red arrows).
As hemosiderin (an iron pigment resulting from hemoglobin
degradation) is common in canine spleen tissue, we sug-
gested that this brown staining in H&E and nonimmune
samples of normal canine spleen belongs to hemosiderin
deposits. Indeed, this suggestion was easily confirmed using
iron staining (Figure 2H, green arrows). This differential
diagnostic approach is most relevant to canine HSA, where
the spleen is the most common site. It is irrelevant and un-
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Figure 1. Immunohistochemical analysis of Gal-3 expression using TIB-166 rat anti –Gal-3 monoclonal antibody in human ASA (A and B) and canine HSA (C and
D). Brown staining in (A) and (C) represents Gal-3 immunoreactivity. (B) and (D) show corresponding negative controls omitting a primary antibody. (E–H) An
example of the computer-assisted analysis of images shown in (C) and (D) using ImageProPlus software. The results of a computer-assisted analysis correlated
well with the scores made by the observers in samples with high and moderate Gal-3 expressions. However, in samples with negative or weak Gal-3 expression,
computer-assisted analysis yielded often elevated (false-positive) scores. Slides were counterstained with hematoxylin. Scale bars, 100 m.
Table 1. Expression of Gal-3 in Human ASA Specimens.
ASA Specimens
Number of Specimens Showing the Slated
Degree of Immunoreactivity
Location Number Examined 0 1+ 2+ 3+
Skin 3 0 1 2 0
Bone 1 0 0 0 1
Scalp 1 0 0 0 1
Breast 2 0 0 0 2
Ileum 1 0 1 0 0
Liver 2 0 0 1 1
Total 10 0 2 3 5
Table 2. Expression of Gal-3 in Canine HSA Specimens.
HSA Specimens
Number of Specimens Showing the Slated
Degree of Immunoreactivity
Location Number Examined 0 1+ 2+ 3+
Spleen 6 0 2 3 1
Omentum 1 0 1 0 0
Skin 6 0 4 2 0
Muscle 2 0 1 0 1
Bone 2 0 2 0 0
Total 17 0 10 5 2
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necessary, however, in human ASA, which occurs most
commonly in cutaneous tissues.
Consequences of Gal-3 Inhibition in Malignant
Endothelial Cells
Next, we investigated whether Gal-3 expression in ma-
lignant endothelial cells plays a significant biologic role in
tumor cell growth and survival in vitro. We have used two
carbohydrate-based Gal-3 inhibitors, MCP [29–31] and LL
[32,33], to evaluate their effects on malignant endothelial
cell clonogenic survival and growth, as well as on tumor cell
sensitivity to chemotherapy. In these experiments, due to
the unavailability of human ASA cell lines, we used murine
SVR ASA cells [34]. First of all, we investigated whether,
similarly to human ASA and canine HSA, murine SVR cells
express Gal-3. Both immunohistochemical (Figure 3A) and
Western blot (Figure 3B) analyses demonstrated that SVR
cells express significant Gal-3 amounts.
After confirming the presence of our target protein in SVR
cells, we investigated how various concentrations of MCP
and LL affected the clonogenic survival and growth of SVR
cells. In clonogenic survival experiments, we plated SVR
ASA cells at low density (200 cells/well in 24-well plates)
in various concentrations of either MCP (0–0.5%) or LL
(0–1.0 mM). Seven days later, colonies of z 15 cells were
scored. The results of these experiments (Figure 4, A–C)
demonstrated that both carbohydrate-based Gal-3 inhibitors
reduced the clonogenic survival of SVR cells in a dose-
dependent manner.
When tumor cells are plated at low density as in clono-
genic survival assays, the majority of cells die by execution
of apoptosis, with only a small fraction surviving and giving
rise to new clones. Thus, we suggested that the inhibitory
effect of MCP and LL on clonogenic survival is likely due
to the inhibition of a Gal-3 antiapoptotic function. Indeed,
when we performed TUNEL assay 24 hours after plating
SVR cells for clonogenic survival, we found that both MCP
and LL reduced significantly the percentage of TUNEL-
negative (nonapoptotic) cells compared to untreated con-
trols (Figure 4, D–F ). These results indicate that the effect
of the carbohydrate-based Gal-3 inhibitors MCP and LL on
HSA cells is associated, in part, with a decrease in tumor
cells’ ability to resist apoptosis.
This outcome naturally led us to the next hypothesis.
Because the majority of currently used cytotoxic drugs act
on cancer cells by inducing apoptosis and because the
carbohydrate-based Gal-3 inhibitors MCP and LL reduce
tumor cell resistance to apoptosis, we hypothesized that
Gal-3 inhibitors would increase the sensitivity of neoplastic
cells to cytotoxic drugs. To test this hypothesis, we investi-
gated next whether MCP and LL sensitize ASA cells to
doxorubicin, a chemotherapeutic drug commonly used to
treat canine HSA. From clonogenic survival experiments,
we determined the ICmin (the minimal concentration of a drug
causing a statistically significant effect) for MCP and LL
at 0.06% and 200 mM, respectively. When applied at ICmin,
MCP and LL caused f30% and f20% inhibition of SVR
clonogenic survival, respectively. Next, we used clonogenic
Figure 2. Differential diagnosis between Gal-3 and hemosiderin staining in canine splenic HSA samples. In (A) – (D), an HSA sample was characterized using H&E
staining (A), anti –Gal-3 antibody (B), nonimmune control (C), and anti –von Willebrand factor polyclonal antibody (D). Brown staining in (B) indicates Gal-3
immunoreactivity. Brown staining in (D) shows von Willebrand factor immunoreactivity consistent with the endothelial origin of HSA cells. In (E)– (H), a sample of
normal canine spleen tissue is shown. Note the presence of brown staining material in H&E slides (E, black arrows) and nonimmune control (G, red arrows)
identified as hemosiderin deposits using Prussian blue stain for iron (H, green arrows). Scale bar shown in (H), 100 m.
Figure 3. Immunohistochemical analysis (A) and Western blot analysis (B)
confirmation of Gal-3 expression in the murine ASA cell line SVR. In (A),
brown staining indicates Gal-3 immunoreactivity. Note the predominantly
cytoplasmic Gal-3 localization (black arrow) with limited nuclear positivity (red
arrow). In (B), a single Gal-3 immunoreactive band was identified by Western
blot analysis.
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Figure 4. The effect of the small-molecular-weight carbohydrate-based Gal-3 inhibitors MCP and LL on the clonogenic survival of SVR cells. In (A)– (C), SVR cells
were plated at low density (200 cell/well) in 24-well plates in increasing concentrations of MCP (0–0.5%) and LL (0–1 mM). Seven days later, colonies of z 15 cells
were scored. Both MCP (A and C) and LL (B) inhibited the clonogenic survival of SVR cells in a dose-dependent manner. TUNEL analysis (D–G) demonstrated
that the effect of both MCP (D and F) and LL (D and G) on SVR clonogenic survival was associated with a significant reduction in the percentage of TUNEL-
negative (nonapoptotic) cells in samples treated with MCP (F) and LL (G) compared to untreated control (E). Note the presence of nonapoptotic cells in the
untreated control (E, black arrows) versus an almost complete absence of TUNEL-negative cells in samples treated with MCP (F) or LL (G).
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survival assay to titrate the effect of doxorubicin on SVR
cells alone or on the background of the ICmin of MCP or
LL. As expected, doxorubicin alone inhibited the clonogenic
survival of SVR cells in a dose-dependent manner (Figure 5),
and this effect was even greater when doxorubicin was used
in combination with the ICmin of MCP (Figure 5A) or LL (Fig-
ure 5B). To determine whether the enhanced inhibition of
SVR clonogenic survival noted after a combined application
of doxorubicin and carbohydrate-based Gal-3 inhibitors
resulted from a simple summation of their respective effects
as single agents, or whether MCP and LL indeed sensitized
ASA cells to doxorubicin, we generated a projected ‘‘would-
be-additive-effect’’ line by extrapolating the effects of MCP
and LL ICmin to the doxorubicin dose-dependent effect (Fig-
ure 5, A and B, red line). For both compounds, the graphs
representing the actual combined effects of doxorubicin
with MCP and LL were significantly shifted to the left com-
pared to would-be-additive-effect graphs (Figure 5, A and
B), providing evidence that both MCP and LL synergize
with doxorubicin by sensitizing ASA cells to this chemo-
therapeutic drug. Indeed, this sensitization was sufficient to
reduce doxorubicin IC50 by 10.7-fold (0.0075–0.0007 mg/ml)
and 3.6-fold (0.0075–0.0021 mg/ml) by MCP and LL, respec-
tively (Figure 5C).
Discussion
Identifying newmolecular targets for cancer therapy, including
mechanism-based combination therapy, may lead to more
potent synergistic effects on tumor growth and metastasis.
In recent years, a b-galactoside–binding lectin, Gal-3, has
attracted increasing attention as a potential therapeutic tar-
get in several cancers, such as breast cancer [14,19,20,31],
prostate cancer [19,20,30], colon cancer [31], gastric cancer
[11,12], and multiple myeloma [35]. Here, we demonstrated
that Gal-3 is expressed widely in human and canine tumors
arising from malignant endothelia and could be targeted
efficiently by the small-molecular-weight carbohydrate-based
inhibitors MCP and LL. Until recently, MCP and LL were
studied mostly for their potential to control and prevent
hematogenous cancer metastasis through inhibition of Gal-
3–mediated metastatic cell homotypic and heterotypic aggre-
gation and adhesion [19,20,30,31,33]. Recent experimental
evidence demonstrating that Gal-3 is also an important regu-
lator of programmed cell death with potent anti-apoptotic
activity [10,23–26] suggests that these same inhibitors may
have potential to sensitize neoplastic cells to cytotoxic drug–
induced apoptosis, thus enhancing their antineoplastic ef-
fects on cancer cells. Although the precise molecular mecha-
nisms by which Gal-3 exerts its antiapoptotic function are not
understood, several key molecular and cellular events asso-
ciated with this process have been identified. It has been
shown that, in response to apoptosis induced by cytotoxic
drugs (including doxorubicin, which was used in this study),
Gal-3 translocates from the nuclei (where it undergoes phos-
phorylation by casein kinase 1 at Ser6) to the cytoplasm [25],
specifically to perinuclear membranes [26], where it effectively
protects mitochondrial integrity, prevents cytochrome c re-
lease [26], and downregulates caspase cascade [24–26]. At
least two distinct molecular pathways, activation of mitogen-
activated protein kinase (ERK and JNK) pathways [25] and
downregulation of Bad expression accompanied by increased
Bad phosphorylation [24], are ultimately involved in Gal-3
antiapoptotic action. Based on this information, it appears
that, to inhibit Gal-3 antiapoptotic effects, carbohydrate-based
compounds such as MCP and LL interact with intracellular
Gal-3. Indeed, extracellular Gal-3 does not protect cancer
cells from apoptosis [26]. This may explain why anti–Gal-3
antibody only blocks Gal-3–mediated adhesion [36] but
does not inhibit Gal-3 antiapoptotic function. It appears that
smaller-molecular-weight carbohydrate-based compounds
are required to interact with intracellular Gal-3. Thus, using
small-molecular-weight carbohydrate-based compounds for
inhibiting Gal-3 antiapoptotic function may represent a new
Figure 5. The effect of the carbohydrate-based Gal-3 inhibitors MCP and LL on SVR cell sensitivity to doxorubicin. Both MCP (A) and LL (B) sensitize SVR cells to
doxorubicin. Note the significant shift to the left of graphs representing a combined effect of doxorubicin with the ICmin of MCP (A, open circles) and LL (B, open
circles) compared to the effect of doxorubicin alone (A and B, closed circles), or a would-be-additive-effect graph (A and B, red line) on the clonogenic survival of
SVR. (C) In vitro IC50 of doxorubicin alone or in combination with the ICmin of MCP (0.06%) or LL (200 M).
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exciting approach for augmenting cytotoxic drug effects on
cancer cells. Indeed, recent work from Chauhan et al. [35]
has demonstrated that MCP sensitizes multiple myeloma
cells to cytotoxic drugs by inhibiting Gal-3 antiapoptotic func-
tion in the mitochondrial apoptosis pathway. Similarly, it ap-
pears that the mechanism of the antineoplastic effect of
the carbohydrate-based Gal-3 inhibitors MCP and LL on
ASA cells is also associated, in part, with the inhibition of
Gal-3 antiapoptotic function in malignant endothelial cells.
Consequently, both MCP and LL reduce the clonogenic sur-
vival of ASA cells and increase their sensitivity to doxorubicin-
induced apoptosis. This sensitization is sufficient to cause a
10.7-fold and 3.6-fold reduction in the IC50 of doxorubicin by
MCP and LL, respectively.
Because of the limitations of surgery, the chemothera-
peutic agent doxorubicin is currently the standard of care
for dogs with HSA. However, even for dogs diagnosed
with early-stage disease and undergoing chemotherapy,
the 1-year survival rate rarely exceeds 10%. The cumulative
cardiotoxic effects of doxorubicin on dogs and humans limit
the ability to escalate drug dose in the hopes of improving its
antitumor efficacy. Inhibition of antiapoptotic proteins, such
as Gal-3, in cancer cells offers the promise of increasing
the efficacy of doxorubicin and other chemotherapeutics
while reducing their associated toxicities.
Currently, different groups explore multiple approaches to
improving the efficacy of radiation therapy and chemotherapy
on cancer cells. For example, the potential for increasing the
effect of radiation therapy by inhibiting oncogenic K-Ras sig-
naling is actively explored [37]. Various strategies for inhibiting
antiapoptotic Bcl-2 family members to enhance tumor cell
apoptotic responses to chemotherapy are being developed
[38,39]. Galectins are emerging as promising molecular tar-
gets for cancer therapy, and galectin inhibitors might have the
potential to be used as antitumor and antimetastatic agents.
Targeting cancer cell adhesive interactions mediated by Gal-3
and its binding partner Thomsen-Friedenreich antigen using
function-blocking antibodies efficiently inhibited metastatic
cancer spread in vivo [40]. In addition to that, it appears that
carbohydrate-based anti–Gal-3 therapies show promise for
the treatment of cancer by enhancing the effects of cytotoxic
drugs. A better understanding of the role of galectins in can-
cer might lead to novel clinical applications for diagnostic
and therapeutic purposes. With these, the use of spontane-
ously developing tumors in large mammalian species (such
as dogs) as models for testing new therapeutic strategies
and modalities has been increasingly appreciated in recent
years [7,41]. Thus, the results presented in this study warrant
further expansion of this work to a species with naturally
occurring HSA, such as dogs, which may serve as an in-
valuable model for the development and evaluation of new
therapeutic strategies.
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